Company profile
Minervax company profile
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Business identity
- Website
- http://minervax.com/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00001-00010 employees
- Revenue range
- $1K+
- Founded
- 2010-01-01
Headquarters
- Headquarters
- Copenhagen, Capital Region, Denmark
- Postal code
- 2200
- Country code
- DK
- Continent
- Europe